Vireo Growth Inc.

VREOF OTC CIK: 0001771706

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation British Columbia, Canada
Business Address 207 SOUTH 9TH STREET, MINNEAPOLIS, MN, 55402
Mailing Address 207 SOUTH 9TH STREET, MINNEAPOLIS, MN, 55402
Phone 604-617-5421
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2024

-$28.01M
Net Income
$278.86M
Total Assets
$199.31M
Total Liabilities
$55.56M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report December 30, 2025 View on SEC
4 Insider stock transaction report December 30, 2025 View on SEC
4 Insider stock transaction report December 30, 2025 View on SEC
8-K Current report of material events December 30, 2025 View on SEC
4 Insider stock transaction report December 30, 2025 View on SEC
4 Insider stock transaction report December 30, 2025 View on SEC
8-K Current report of material events December 29, 2025 View on SEC
8-K Current report of material events December 22, 2025 View on SEC
8-K Current report of material events December 10, 2025 View on SEC
S-3 Shelf registration for future offerings December 9, 2025 View on SEC

Material Events

8-K Acquisition December 22, 2025
High Impact
  • Vireo Growth Inc., through its subsidiary, is acquiring cannabis dispensary assets in Colorado from PharmaCann Inc.
  • The acquisition is valued at approximately $49 million, primarily paid with Vireo's company shares, and includes taking on some of PharmaCann's related debts.
View Analysis
8-K Acquisition December 10, 2025
High Impact
  • Vireo Growth Inc., through its subsidiary, acquired a majority of Medicine Man Technologies, Inc. (Schwazze) assets.
  • The acquisition was executed via a 'credit bid' using approximately $111 million of Schwazze's Senior Secured Convertible Notes during its restructuring process.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.